此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Thyroid Cancer in United Arab Emirates

2021年2月17日 更新者:Khaled M Aldahmani、Tawam Hospital

Decline in Radioiodine Use But Not Total Thyroidectomy in Thyroid Cancer Patients Treated in United Arab Emirates- A Retrospective Study

The main objective of the study is to assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer in the largest oncology center in the United Arab Emirates (UAE).

研究概览

详细说明

The aim of this study is to assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer (TC) in the largest oncology center in the United Arab Emirates (UAE).

This study was conducted in Tawam hospital (TWM), which provides tertiary care services to patients in the UAE. It is the only center delivering radioactive iodine (RAI) therapy and radiotherapy in Al Ain city. Most TC patients are followed in designated TC clinics within the endocrinology division or less commonly through other clinics (surgery, radiation, or medical oncology). The hospital runs monthly multidisciplinary team-based discussions on patients with TC, wherein decisions regarding RAI treatment and dose selection are determined jointly by nuclear medicine physicians and endocrinologists.

We retrospectively evaluated all patients with TC presenting to TWM during the period of September 2008 and December 2018. The beginning of data collection (September 2008) reflects the inception time of electronic medical records (EMRs) use in the hospital. Cases of TC were extracted from the EMRs using the International Classification of Disease 9 & 10 codes (193 & c73). Other variables were demographic information, year of diagnosis, type of TC, histopathological subtype, lymph node (LN) involvement, type of thyroid surgery, use of RAI treatment, and radiation therapy. The extent of surgery, the exact details of histopathology, and the RAI dose were retrieved from the respective specialty reports. Tumor staging was reported according to the 8th edition of the American joint committee on cancer (AJCC)/TNM staging system [16]. Those with incorrect pathological diagnosis, incomplete data, or noninvasive follicular type PTC were excluded.

The data were extracted using Microsoft Excel 2015 and imported into Stata 16.0 for statistical analysis. Continuous variables were described using means and standard deviations (±SD). Categorical variables were described as frequency distributions. Variables of clinical features and management were cross tabulated with the year of diagnosis and exact logistic and ordinal logistic regressions were performed to analyze the annual trend in features and management of TC as appropriate. The results of relative trend were reported as odds ratio (OR) with an overall ptrend. The OR=1 indicated no change over years, OR <1 indicated a decline, while OR >1 indicated an increase over years. Simple and multiple logistic regression analysis were performed to assess the unadjusted and adjusted association of management of TC (RAI, surgical management) with age, gender, nationality, year of diagnosis, tumor subtype, and other co-variates. The results of simple and multiple logistic regression were reported as odd ratios (OR) and adjusted odds ratios (AOR) respectively with their corresponding 95% confidence intervals (CI) and p-values.

研究类型

观察性的

注册 (实际的)

762

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

All patients with Thyroid Cancer presenting to Tawam Hospital during the period of September 2008 and December 2018. Those with incorrect pathological diagnosis, incomplete data, or noninvasive follicular type PTC were excluded.

描述

Inclusion Criteria:

  • All patients with Thyroid Cancer presenting to Tawam Hospital during the period of September 2008 and December 2018.

Exclusion Criteria:

  • Patients with inadequate data, noninvasive follicular type PTC and incorrect pathological diagnosis,

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Thyroid Cancer Cases
It is a retrospective study

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Clinicopathological features
大体时间:September 2008- December 2018
Assess clinicopathological features of thyroid cancer patients
September 2008- December 2018
Extent of surgery
大体时间:September 2008- December 2018
Assess extent of surgery in thyroid cancer patients and changes over time
September 2008- December 2018
Use of RAI
大体时间:September 2008- December 2018
Evaluate the use of RAI in thyroid cancer patients and assess predictors of RAI Rx
September 2008- December 2018

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2008年9月1日

初级完成 (实际的)

2018年12月1日

研究完成 (实际的)

2020年12月1日

研究注册日期

首次提交

2021年2月9日

首先提交符合 QC 标准的

2021年2月17日

首次发布 (实际的)

2021年2月21日

研究记录更新

最后更新发布 (实际的)

2021年2月21日

上次提交的符合 QC 标准的更新

2021年2月17日

最后验证

2021年2月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅